Skip to content

US · ONC · BIOTECHNOLOGY

BeOne Medicines AG (ONC) intrinsic value and stock valuation

$390.94as of 2026-11-21 · Mkt cap 37.22B

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

BeOne Medicines AG DCF and intrinsic value

InvestorsCraft values ONC with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from ONC’s statements →

BeOne Medicines AG Graham Number

Graham Number: $48.65d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Biotechnology Basel, PA 4051 beonemedicines.com

How the business is doing

Fiscal 2013–2025, USD

Revenue
$5.34B+76.8% 5y CAGRd
20132025
Net income
$286.9M
20132025
Free cash flow
$941.7M
20132025
Total equity
$4.36B+2.4% 5y CAGRd
20132025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2013–2025, USD
20252024202320222021
Revenue$5.34B$3.81B$2.46B$1.42B$1.18B
Operating income$447.1M-$-568.2M-$-1.21B-$-1.79B-$-1.44B
Net income$286.9M-$-644.79M-$-881.71M-$-2B-$-1.46B
EPSd$2.53M-$-6.12M-$-8.45M-$-19.43M-$-15.71M
Operating cash flow$1.13B-$-140.63M-$-1.16B-$-1.5B-$-1.3B
Capital expenditure-$-185.84M-$-529.14M-$-596.26M-$-469.1M-$-314.85M
Free cash flow$941.7M-$-669.77M-$-1.75B-$-1.97B-$-1.61B
Total assets$8.19B$5.92B$5.81B$6.38B$8.54B
Total debt$2B$1.08B$930.2M$596.7M$694.6M
Net debt-$-2.55B-$-1.55B-$-2.24B-$-3.27B-$-3.68B
Total equity$4.36B$3.33B$3.54B$4.38B$6.13B
Cash and short-term investments$4.55B$2.63B$3.17B$4.53B$6.62B
Income statement
20252024202320222021
Revenue$5.34B$3.81B$2.46B$1.42B$1.18B
Cost of revenue$668.5M$594.1M$379.9M$286.5M$164.9M
Gross profit$4.67B$3.22B$2.08B$1.13B$1.01B
Research and development expenses$2.15B$1.95B$1.78B$1.64B$1.46B
Selling, general and administrative expenses$2.08B$1.83B$1.51B$1.28B$990.1M
Other expenses$0.00$0.00$0.00$0.00$750K
Operating expenses$4.23B$3.78B$3.29B$2.92B$2.45B
Cost and expenses$4.9B$4.38B$3.67B$3.21B$2.62B
Interest income$70.5M$47.8M$74M$52.5M$15.8M
Interest expense$58.2M$0.00$0.00$0.00$0.00
Depreciation and amortization$141.7M$171.8M$87.7M$66.3M$46.5M
Ebitda$616.8M-$-361.24M-$-738.16M-$-1.89B-$-1.39B
Operating income$447.1M-$-568.2M-$-1.21B-$-1.79B-$-1.44B
Total other income/expenses, net-$-30.28M$35.2M$381.9M-$-171.37M$150K
Income before tax$416.9M-$-533M-$-825.84M-$-1.96B-$-1.44B
Income tax expense$129.9M$111.8M$55.9M$42.8M$19.2M
Net income$286.9M-$-644.79M-$-881.71M-$-2B-$-1.46B
Weighted average shares outstanding$109.1M$105.3M$104.4M$103.1M$92.8M
Weighted average diluted shares outstanding$113.5M$105.3M$104.4M$103.1M$92.8M
Balance sheet
20252024202320222021
Cash and short-term investments$4.55B$2.63B$3.17B$4.53B$6.62B
Net receivables$886.9M$709.1M$395.9M$199M$500.2M
Inventory$608.2M$495M$416.1M$282.4M$242.6M
Total current assets$6.23B$3.99B$4.2B$5.21B$7.61B
Property, plant and equipment, net$1.79B$1.66B$1.37B$924M$662.5M
Goodwill and intangible assets$62.7M$129.8M$108.9M$94.6M$103.5M
Long-term investments$82.5M$128.9M$89.6M$91.8M$100.8M
Total non-current assets$1.95B$1.93B$1.6B$1.17B$921.6M
Total assets$8.19B$5.92B$5.81B$6.38B$8.54B
Accounts payable$479M$405M$315.1M$294.8M$262.4M
Short-term debt$134.7M$869.1M$710.3M$353M$449.5M
Deferred revenue$0.00$0.00$0.00$213.9M$187.4M
Total current liabilities$1.83B$2.21B$1.81B$1.47B$1.6B
Long-term debt$1.87B$210.8M$219.9M$243.7M$245.2M
Deferred revenue, non-current$0.00$30.3M$34.2M$80.2M$266.6M
Total non-current liabilities$2.01B$373.8M$457.8M$527.4M$803.4M
Capital lease obligations$52.9M$61.9M$44.2M$58.6M$65M
Total liabilities$3.83B$2.59B$2.27B$2B$2.4B
Common stock$140K$140K$140K$140K$130K
Retained earnings-$-8.32B-$-8.61B-$-7.96B-$-7.08B-$-5.08B
Accumulated other comprehensive income (loss)-$-78.18M-$-148.99M-$-99.45M-$-77.42M$18M
Total equity$4.36B$3.33B$3.54B$4.38B$6.13B
Total investments$82.5M$128.9M$92.2M$757M$2.34B
Total debt$2B$1.08B$930.2M$596.7M$694.6M
Net debt-$-2.55B-$-1.55B-$-2.24B-$-3.27B-$-3.68B
Cash flow statement
20252024202320222021
Net income$286.9M-$-644.79M-$-881.71M-$-2B-$-1.41B
Depreciation and amortization$141.7M$171.8M$87.7M$66.3M$46.5M
Stock-based compensation$510.9M$441.6M$367.6M$303.2M$240.7M
Change in working capital$191.4M-$-157.17M-$-370.54M$132.4M-$-118.34M
Accounts receivable-$-164.95M-$-329.44M-$-188.31M$304.1M-$-423.02M
Inventory-$-93.17M-$-91.5M-$-140.95M-$-56.69M-$-153.33M
Accounts payable$79.8M$121.5M$21.5M-$-4.35M$20M
Net cash provided by operating activities$1.13B-$-140.63M-$-1.16B-$-1.5B-$-1.3B
Investments in property, plant and equipment-$-185.84M-$-492.66M-$-561.9M-$-469.1M-$-314.85M
Acquisitions, net$0.00$0.00$0.00-$-1.4B$51.9M
Net cash used for investing activities-$-276.15M-$-548.35M$60M$1.08B$640.7M
Common stock issued$196.8M$0.00$0.00$0.00$3.44B
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$1.06B$193.5M$416.5M-$-18.97M$3.64B
Net change in cash$1.97B-$-547.24M-$-689.05M-$-507.85M$2.99B
Cash at end of period$4.61B$2.64B$3.19B$3.88B$4.38B
Operating cash flow$1.13B-$-140.63M-$-1.16B-$-1.5B-$-1.3B
Capital expenditure-$-185.84M-$-529.14M-$-596.26M-$-469.1M-$-314.85M
Free cash flow$941.7M-$-669.77M-$-1.75B-$-1.97B-$-1.61B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About BeOne Medicines AG

        BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.

        CEO
        John V. Oyler
        Employees
        12K
        Beta
        0.49

        Explore

        Frequently asked questions

        What is the intrinsic value of BeOne Medicines AG (ONC)?

        BeOne Medicines AG (ONC) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ONC undervalued?

        ONC trades at a price of $390.94 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.